Linked Oncology Data Quality Crucial for Cancer Care Advancement

🩺 SPOTLIGHT ON ONCOLOGY | Part 1:Hidden Numbers & The "Rare Disease" Illusion 📌 7️⃣ PART 1 Data Wrap-Up Over the past series of posts, we’ve looked at how "rare" cancer labels are often created by statistical blind spots: 🧑🧒🧒Uncounted populations (The Denominator Problem) 🛃Hospital-only data gathering (The Tip of the Iceberg Effect) ❤️🩹Diagnostic delays mislabeled as late presentation (Diagnostic Lag) 🔢Distorted survival numbers (Lead-Time Bias) 🚺Mismatched population baselines (Age Profile Distortion) 🌗Incomplete death recording (The Missing Cause of Death) As clinicians, researchers, and data analysts, we cannot take textbook statements at face value. When an oncology textbook labels a disease as "rare" in our setting, our first question should always be: Show me the registry behind that number. If the data pipeline is broken, the conclusion is an assumption, not a fact. What is one textbook statistic in your specialty that you believe severely underestimates local reality? 📌 Follow #SpotlightOnOncology for ongoing discussions challenging assumptions in cancer care, research, and healthcare data. #SpotlightOnOncology #EvidenceBasedMedicine #DataTransparency #OncologyCare #HealthcareData

Interim overall survival (OS) analyses can influence critical clinical and regulatory decisions, despite often being based on immature data. How can sponsors and regulators better interpret these results and assess potential treatment-related harm? Join Friends of Cancer Research on Wednesday, July 15 for Interpreting Interim Overall Survival (OS) for Decision-Making, a webinar exploring a simulation-informed framework designed to support more informed interpretation of interim OS findings in oncology trials. We're pleased that Andrew Mills, Strategic Principal Statistician at MMS, will join a panel of experts to discuss practical considerations for applying this framework in trial design, data interpretation, and regulatory decision-making. Register here: https://hubs.li/Q04pkF3B0 #OncologyResearch #ClinicalTrials #Biostatistics #DrugDevelopment #RegulatoryScience #CancerResearch #ClinicalDevelopment #DataScience #FriendsOfCancerResearch #OneMMS

Trial imaging error rates run as high as 25 to 50%, even at leading cancer centers. Those errors put data integrity and patient outcomes at risk. Yunu enforces protocol-compliant reads and automated accuracy checks at every site, cutting error rates to under 2%. Accuracy should start at the source, not central review. Explore how Yunu supports cancer centers at https://zurl.co/6wiCd. #ClinicalTrials #OncologyResearch #DataIntegrity #MedicalImaging #CancerResearch

A 25–50% error rate isn’t a review problem. It’s a workflow problem. The best place to catch an imaging error is before it happens.

$110B by 2030. That's where the women's oncology market is headed. New market-sizing data reported by MedCity News puts the global women's oncology market at $110B by 2030 — driven by expanding treatment pipelines and better diagnostics. Here's the part that doesn't make the headline: the growth curve and the access curve aren't moving together. Significant gaps remain in early detection, diagnosis, and funding for cancers that specifically affect women. A market can triple in size and still leave the people it's supposed to serve behind. That gap is exactly where the next wave of investable infrastructure gets built — diagnostics, navigation, reimbursement pathways. OVUM tracks where oncology capital and access are converging (and where they aren't) — daily. Full signal + what we're watching next → ovum.live Follow OVUM for the daily read on women's health Beta access is open if you want it first #WomensHealth #Oncology #HealthTech #MarketIntelligence #femtech #Womenfounders

🤝 Helping people make informed choices about research participation Taking part in research is an important decision, and having clear, trusted information available can help patients, families and communities feel more confident when considering their options. Following the launch of our consumer co-designed animated explainer video, we are pleased to share our new companion brochure: a practical guide designed for patients and families to revisit, share and use when learning about biobanking and participation in TRACKER Biobank. Developed in partnership with our Consumer Committee, the brochure was shaped by the experiences, questions and perspectives of people affected by lung cancer. Their insights have been central to creating a resource that reflects what matters most to the community. 🗣️ Together, the animated video and brochure provide different ways for people to engage with TRACKER — whether through watching, reading, or having conversations with their support networks. We are very grateful to our Consumer Committee members for their expertise, commitment and partnership in helping ensure research resources are developed with, and for, the communities they aim to serve. Thank you for your continued support! Learn more: https://lnkd.in/gtuE_siz ___ #TRACKERBiobank #ConsumerEngagement #LungCancerResearch #HealthEquity #PatientCentredResearch #Biobanking

When people talk about #cancerresearch, they usually focus on the breakthrough. What often goes unnoticed are the years of dedication behind it. Long hours in laboratories, clinical trials, patient participation, and researchers who keep searching for answers, one step at a time. Real progress doesn't happen overnight. Every study, every piece of data, and every lesson learned brings us closer to better treatments and, hopefully, better outcomes for millions of people. Cancer research reminds us that lasting impact comes from patience, evidence, and the commitment to keep learning. The same is true for every important decision. The best outcomes come from understanding people through research instead of relying on assumptions. At TeamVisory, we believe real human insights are the foundation of better decisions. #CancerResearch #ResearchMatters #HealthcareInnovation #MedicalResearch #HumanInsights #MarketResearch #TeamVisory Hemant Arora Kapil Narang Devinder Malhotra Rakhi Kashyap Nitin Kumar Ashish Dixit Naman Kumar

Your target validation just got a major upgrade! 𝐓𝐚𝐥𝐤𝟐𝐃𝐚𝐭𝐚 𝐕𝟔 now shows how a target performs in real patients, enriched with cell-level clinical metadata. Treatment response. Cancer/tumor stage. Remission. Relapse. Developmental stage. Demographics. 𝐖𝐡𝐚𝐭'𝐬 𝐧𝐞𝐰: 🔹 20.8M cells with treatment response annotations across 861 treatments 🔹 Cancer staging + TNM data across tumor stages 🔹 Drug combos preserved: combo vs. monotherapy, no manual curation 🔹 899 anatomical sites: matched normal, diseased, tumor, metastatic tissue 🔹 1,206 cell types under one harmonized ontology 🔹 4,493 studies · 85,934 samples · 1,076 diseases 298.8M human single-cell records with clinical-grade metadata. 4,493 studies. Part of a 700M+ cell multi-omics database. No more guessing. No more inferring from diagnosis alone. 👉 𝐀𝐥𝐫𝐞𝐚𝐝𝐲 𝐚 𝐓𝐚𝐥𝐤𝟐𝐃𝐚𝐭𝐚 𝐮𝐬𝐞𝐫? 𝐋𝐨𝐠 𝐢𝐧 𝐚𝐧𝐝 𝐞𝐱𝐩𝐥𝐨𝐫𝐞 𝐭𝐡𝐞 𝐧𝐞𝐰 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐬 𝐭𝐨𝐝𝐚𝐲: talk2data.bioturing.com 👉 𝐍𝐞𝐰 𝐭𝐨 𝐓𝐚𝐥𝐤𝟐𝐃𝐚𝐭𝐚? 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐚 𝐝𝐞𝐦𝐨 𝐚𝐧𝐝 𝐬𝐞𝐞 𝐢𝐭 𝐢𝐧 𝐚𝐜𝐭𝐢𝐨𝐧! #BioTuring #Talk2Data #SingleCellGenomics #DrugDiscovery #Genomics #Bioinformatics #PrecisionMedicine

Returning from #PPLC2026 reminded me how much work is still ahead in blood cancers. While the science continues to advance, meetings like PPLC reinforce that progress only happens when researchers, clinicians, advocates, and industry come together around a shared goal: changing what's possible for patients. I'm leaving with a deeper appreciation for the conversations, new data shared and for the people across this community who continue to put patients first. Thank you to the organizers, speakers, and everyone who contributed to such a thoughtful and impactful meeting. Looking forward to seeing how today's discussions translate into tomorrow's breakthroughs. #PPLC2026 #PPLC #Lymphoma #HealthEquity #PFEColleague

Over half of therapy switching events among 35,000 US #prostate #cancer patients in this Indegene study occurred within the first 60 days of treatment, with many transitions planned rather than reactive. Vikas Mahajan, Associate Vice President, Data, Analytics and AI, Indegene, outlines how switching is rarely driven by just clinical progression; payer dynamics, access barriers such as plan limitations and refill restrictions, and treatment-continuity patterns were among the influential predictors — with payer channel ranking second only to treatment gaps as a model driver. Interestingly, certain #physician segments, particularly urology-led settings, emerged as a notable hotspot with higher switching rates, presenting a targeted physician engagement opportunity for pharma. That and more in this piece. https://lnkd.in/d8msEqrM